Acquire YCANTH™ through a streamlined acquisition model

Verrica has partnered with FFF Enterprises, Inc. to offer a consigned inventory program for your practice

Photo is for illustrative purposes only.

STEP 1

Open an account with FFF to order YCANTH inventory

FFF provides customizable options for managing inventory in your practice. Once you’ve completed your setup, FFF will ship YCANTH directly to your practice.

  • Register a new account with FFF Enterprises
  • Your FFF Sales Representative will help you complete your account setup and initiate access to consigned inventory
  • If you need additional support, you can reach the FFF sales team directly by phone at 1-800-843-7477 or by email at SDRTeam@fffenterprises.com

STEP 2

Sign up for support from Y-Access™ Support Solutions

Y-Access can assist with patient benefit investigations and automated copay enrollment for eligible patients.

After you have registered your practice, forms can be completed directly on Y-AccessSupport.com.

Get Started Now

Y-Access Support Solutions is here to help:

1-855-YCANTHS (1-855-922-6847)

Y-AccessSupport.com

Prescribe YCANTH through our dedicated Specialty Pharmacy, Nufactor®

Simplified prescribing process

Prescriptions can be submitted through your electronic Rx (ERx): choose YCANTH in the drop-down menu

OR

By phone at 1-800-315-0155

By fax at 1-800-267-4982

NDC: 71349-070-01
Rx: YCANTH (cantharidin) topical
solution, single applicator

NDC=National Drug Code.

NuFactor will manage all additional requirements for patient care:

  • Contact the patient about their out-of-pocket costs and verify insurance coverage prior to treatment
  • Satisfy any insurance requirements
  • Enroll eligible patients in Verrica’s Copay Assistance Program
  • Ship the patient-labeled YCANTH prescription to your practice prior to the next patient visit

For Nufactor support:

www.Nufactor.com/YCANTH

Phone: 1-800-315-0155

Fax : 1-800-267-4982

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.